To evaluate the impact of Ezh2 in CD8+ T-cell responses, we used an experimental ACT model, of which transferred T cells were more effective in controlling tumor growth in lymphopenic mice compared with lymphoreplete hosts4,11,28. The gene discussed is CD8A; the disease is neoplasm.